A Comprehensive Monograph on Crofelemer (DB04941): From Ethnobotany to a First-in-Class Antisecretory Agent

Executive Summary

Crofelemer is a first-in-class, orally administered antisecretory agent approved for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.[1] A novel botanical drug, Crofelemer is a purified oligomeric proanthocyanidin extracted from the red bark latex of the South American tree,

Croton lechleri.[1] Its development represents a significant milestone, bridging traditional ethnobotanical knowledge with modern, evidence-based pharmaceutical science. The drug's therapeutic effect is mediated by a unique, localized mechanism of action within the gastrointestinal lumen. It dually inhibits two distinct, structurally unrelated chloride ion channels on the apical membrane of intestinal enterocytes: the cystic fibrosis transmembrane conductance regulator (CFTR) and the calcium-activated chloride channel (CaCC).[1] By modulating these channels, Crofelemer normalizes the intestinal secretion of chloride ions and, consequently, the passive outflow of sodium and water, thereby improving stool consistency and reducing the frequency of watery stools without affecting gastrointestinal motility.[5]

The efficacy and safety of Crofelemer were established in the pivotal Phase 3 ADVENT trial, which demonstrated a statistically significant improvement in clinical response rates for patients treated with Crofelemer compared to placebo.[6] A key feature of Crofelemer's pharmacological profile is its minimal systemic absorption, with plasma concentrations typically below the level of quantitation following oral administration.[1] This property is a direct consequence of its large, polymeric chemical structure and is the primary determinant of its favorable safety profile, which is comparable to that of placebo and characterized by a low incidence of systemic adverse events and drug-drug interactions.[9]

Beyond its approved indication, Crofelemer is the subject of an extensive clinical development program. While a Phase 3 trial for the prophylaxis of cancer therapy-related diarrhea in a broad population did not meet its primary endpoint, subgroup analyses suggest potential efficacy in more homogeneous patient cohorts.[11] Concurrently, a strategic focus has shifted towards rare gastrointestinal disorders, where its antisecretory mechanism is highly relevant. Crofelemer has received multiple Orphan Drug Designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of short bowel syndrome, microvillus inclusion disease, and cholera, signaling a promising future for this unique botanical therapeutic.[1]

Drug Profile and Chemical Characterization

Nomenclature and Identification

Crofelemer is identified by a range of names and chemical codes that reflect its development from an investigational compound to a marketed pharmaceutical. The United States Adopted Name (USAN) for the drug is Crofelemer.[5] It is marketed in the United States under the brand name Mytesi®, having previously been marketed as Fulyzaq®.[8] During its investigational phases, it was known by several code names, most notably SP-303, as well as NP-303 and TRN-002.[1] The synonyms Provir and Virend have also been associated with the compound.[17] For regulatory and scientific purposes, it is cataloged under several key identifiers, which are summarized in the table below.

Attribute	Value	Source(s)
Generic Name	Crofelemer	5
Brand Names	Mytesi® (current), Fulyzaq® (previous)	8
CAS Number	148465-45-6	1
DrugBank ID	DB04941	1
FDA UNII	PY79D6C8RX	1
Chemical Class	Oligomeric Proanthocyanidin	5
Botanical Source	Croton lechleri Müll. Arg.	1
Molecular Formula	(C15O6,7H12)n or C15•nH12•n+2O6.5•n	5
Average Molecular Weight	860–9100 g·mol−1; ~2100 Da (average)	5

Botanical Origin and Ethnomedical Context

Crofelemer is a botanical drug product, a classification that underscores its direct origin from a plant source. It is extracted and purified from the crude red bark latex of Croton lechleri Müll. Arg., a tree belonging to the Euphorbiaceae family that is native to the northwestern and western Amazonian regions of South America.[1] The raw latex is colloquially known as "Sangre de Grado" or "Sangre de Drago," which translates to "Dragon's Blood," a name derived from its vibrant red color.[5]

The development of Crofelemer is a prime example of modern ethnobotany, where traditional medicinal knowledge serves as the foundation for contemporary drug discovery. For centuries, the crude latex of C. lechleri has been a cornerstone of traditional South American medicine.[23] Indigenous communities have used it empirically for a multitude of ailments, including the oral treatment of diarrhea and stomach ulcers, and the topical application for wound healing, inflammation, insect bites, and herpes ulcers.[5] This long history of use for diarrheal illness provided the critical ethnobotanical lead that prompted scientific investigation into its active components and mechanism of action.

Recognizing the importance of the natural source, the manufacturer has established a sustainable harvesting program for the C. lechleri latex. This program operates under fair trade practices, designed to ensure a high degree of product quality and ecological integrity while providing economic support to the local and indigenous communities involved in its collection.[12] This approach addresses the ethical and environmental considerations inherent in the commercialization of a natural product derived from a sensitive ecosystem like the Amazon rainforest.

Chemical Composition and Manufacturing

Crofelemer is not a single chemical entity but rather a complex, purified mixture of polymers, a characteristic that defines both its pharmacology and the regulatory pathway it navigated. It is chemically classified as an oligomeric proanthocyanidin.[5] The polymeric chains are composed of four principal monomer units—(+)–catechin, (–)–epicatechin, (+)–gallocatechin, and (–)–epigallocatechin—that are linked together in a random sequence.[5] This random polymerization results in a heterogeneous mixture of molecules of varying lengths and compositions. The average degree of polymerization, as determined by phloroglucinol degradation, ranges between 5 and 7.5 monomer units.[5]

This structural heterogeneity is reflected in its wide-ranging molecular weight, reported to be between 860 and 9100 g·mol−1, with an average molecular weight often cited as approximately 2100 Da.[5] Its molecular formula is represented in a generalized format, such as

(C15O6,7H12)n or C15•nH12•n+2O6.5•n, which accounts for the variable number (n) of repeating monomer units.[5] Some sources incorrectly list a small molecule formula and weight for Crofelemer, a confusion likely arising from the difficulty of cataloging a complex botanical polymer in standard chemical databases.[17]

The manufacturing process begins with the raw botanical material, the crude latex. This latex is chilled to induce a phase separation, allowing for the removal of solid residues. The remaining supernatant, which contains the active oligomers, is then subjected to a multi-step purification process involving filtration, low-pressure liquid chromatography on an ion-exchange column, and further purification on a Sephadex column, ultimately yielding the purified drug substance after drying.[4] The process has been optimized over time to increase the final yield of the proanthocyanidin mixture.[21]

The unique nature of Crofelemer as a complex botanical drug presented significant Chemistry, Manufacturing, and Controls (CMC) challenges during its regulatory review. Unlike a synthesized new molecular entity, ensuring the identity, strength, purity, quality, and batch-to-batch consistency of a heterogeneous natural product requires a sophisticated and multi-faceted analytical approach.[22] These CMC considerations were a central topic of discussion with the FDA and led to an extension of the drug's initial review period to allow for the submission of additional characterization data.[29] Crofelemer's successful navigation of this process set an important precedent, as it became the first orally administered botanical drug to receive FDA approval, demonstrating a viable regulatory pathway for complex, plant-derived medicines that bridge traditional remedies and modern pharmacology.[23]

Clinical Pharmacology

Mechanism of Action

Crofelemer represents a first-in-class antisecretory antidiarrheal agent, distinguished by a novel mechanism of action that targets the underlying pathophysiology of secretory diarrhea.[5] Its activity is confined to the gastrointestinal lumen, a direct result of its minimal systemic absorption.[9] The primary therapeutic effect of Crofelemer is the normalization of fluid and electrolyte secretion in the intestine through the dual inhibition of two key chloride ion channels located on the apical (luminal) membrane of enterocytes.[1] These two targets are structurally and functionally distinct, and their simultaneous modulation is central to the drug's robust antisecretory effect.

1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): The CFTR channel is a cyclic adenosine monophosphate (cAMP)-stimulated chloride channel that plays a pivotal role in intestinal fluid secretion. Pathogens like Vibrio cholerae and certain disease states can elevate intracellular cAMP, leading to over-activation of CFTR and subsequent high-volume secretory diarrhea.[4] Crofelemer functions as a partial antagonist of the CFTR channel. It acts from an extracellular site on the channel to produce a voltage-independent block, which stabilizes the channel in its closed state, thereby reducing chloride efflux.[4] In vitro studies have quantified this effect, showing that Crofelemer achieves a maximum inhibition of CFTR of approximately 60% with a half-maximal inhibitory concentration ( IC50​) of approximately 7 μM.[4]
2. Calcium-Activated Chloride Channel (CaCC): The CaCC, identified as TMEM16A (or ANO1), is the other primary channel for chloride secretion in the gut, activated by increases in intracellular calcium. Certain HIV proteins and antiretroviral drugs, particularly protease inhibitors, are believed to cause diarrhea by increasing CaCC activity.[31] Crofelemer is a potent inhibitor of this channel, also acting via a voltage-independent mechanism. Its inhibitory effect on CaCC is even more pronounced than on CFTR, with a maximum inhibition of over 90% and an IC50​ of approximately 6.5 μM.[4]

The physiological consequence of this dual channel blockade is a significant reduction in the secretion of chloride ions into the intestinal lumen. Because the movement of sodium ions and water into the gut is osmotically coupled to chloride secretion, inhibiting this primary step effectively halts the entire secretory process.[8] This leads to a normalization of intraluminal fluid volume, resulting in improved stool consistency (less watery) and a reduced frequency of bowel movements.[5]

This antisecretory mechanism is fundamentally different from that of traditional antimotility agents like loperamide or diphenoxylate, which act on opioid receptors in the gut to inhibit peristalsis.[33] By not affecting gastrointestinal motility, Crofelemer avoids common side effects associated with antimotility drugs, such as constipation, abdominal cramping, and rebound diarrhea.[1] This distinction is critical, as it makes Crofelemer particularly well-suited for the chronic management of secretory diarrhea, where slowing transit time is not the primary therapeutic goal and can be counterproductive. Furthermore, the action of Crofelemer is highly selective; it does not impact the function of other key epithelial transporters like sodium or potassium channels, nor does it interfere with the upstream intracellular signaling pathways involving cAMP or calcium.[4]

Pharmacokinetics and Pharmacodynamics

The pharmacokinetic profile of Crofelemer is defined by its chemical nature as a large, hydrophilic polymer, which dictates its behavior in the gastrointestinal tract and is the cornerstone of its safety profile.

Absorption: Following oral administration, the systemic absorption of Crofelemer is minimal to negligible.[1] This has been consistently observed in studies involving both healthy volunteers and HIV-infected patients.[8] Plasma concentrations of the drug are typically below the level of quantitation (50 ng/mL), making it impossible to establish standard pharmacokinetic parameters like area under the curve (AUC) or peak plasma concentration (

Cmax​).[1] This lack of absorption is a direct consequence of its large molecular size and hydrophilic properties, which prevent it from passively diffusing across the lipid-rich membranes of intestinal epithelial cells. Consequently, the drug acts locally within the gut lumen where its targets, the CFTR and CaCC channels, are located.[9]

Effect of Food: The administration of Crofelemer is not significantly affected by food. A study in healthy individuals showed that taking the drug with a high-fat meal did not lead to an increase in systemic exposure.[8] This finding supports the clinical recommendation that Crofelemer can be administered twice daily without regard to meals, which enhances convenience and adherence for patients.[8]

Distribution, Metabolism, and Excretion: As a result of its minimal absorption, the pharmacokinetic parameters related to distribution, metabolism, and excretion have not been characterized. The volume of distribution has not been quantified, and it is unknown whether the drug is distributed into human milk.[1] Similarly, no metabolites have been identified in human plasma, which is consistent with the drug remaining almost entirely within the gastrointestinal tract.[8] The route of elimination from the body has not been formally identified, and the elimination half-life has not been established, as systemic concentrations are too low to measure accurately over time.[1]

Pharmacodynamics: While formal studies on the onset and duration of action are not detailed, the pharmacodynamic effects can be inferred from both in vitro data and clinical trial results. In vitro studies demonstrate that Crofelemer's inhibitory action on the CFTR channel is durable and resists washout, with less than 50% reversal of inhibition observed even after 4 hours.[4] This suggests a prolonged local effect on the intestinal epithelium after a dose. Clinically, data from the ADVENT trial showed a response rate that increased continuously over the 4-week placebo-controlled period and continued to improve during the 20-week open-label extension.[7] This pattern suggests that the therapeutic effect is not acute but rather builds over time with consistent dosing, leading to a sustained normalization of bowel function.

The pharmacokinetic profile is the lynchpin of the drug's overall clinical utility. The near-total lack of systemic absorption directly leads to its favorable safety profile, minimizing the risk of systemic adverse events, organ toxicity (e.g., hepatotoxicity), and systemic drug-drug interactions.[26] However, this same property creates a unique consideration for potential local drug interactions. Because the drug is present at high concentrations within the gut lumen, it has the theoretical potential to inhibit drug-metabolizing enzymes (e.g., CYP3A4) and transporters (e.g., MRP2, OATP1A2) located in the gut wall.[8] This could alter the absorption and bioavailability of other orally co-administered drugs that are substrates for these systems. This potential for localized interaction, despite systemic safety, prompted the FDA to recommend a post-marketing commitment to study this effect in vivo with a sensitive CYP3A4 substrate.[37]

Clinical Evidence and Therapeutic Applications

The clinical development of Crofelemer has spanned multiple diarrheal conditions, with varying degrees of success that have shaped its current therapeutic role and future strategic direction. A summary of the key clinical trials is presented below.

Indication	Trial Name / Identifier	Phase	Study Design	Patient Population (N)	Dosage(s) Studied	Primary Endpoint	Key Result / Outcome
Non-Infectious Diarrhea in HIV/AIDS	ADVENT / NCT00547898	3	Randomized, Double-Blind, Placebo-Controlled, 2-Stage	376	125, 250, 500 mg BID vs. Placebo	% of patients with clinical response (≤2 watery stools/week for ≥2 of 4 weeks)	Met: 17.6% (125 mg) vs. 8.0% (Placebo); p=0.01. Led to FDA approval.
Cancer Therapy-Related Diarrhea (Prophylaxis)	OnTARGET / NCT04538625	3	Randomized, Double-Blind, Placebo-Controlled	287	125 mg BID vs. Placebo	Incidence of diarrhea	Not Met: No statistically significant improvement vs. placebo in broad population.
Irritable Bowel Syndrome with Diarrhea (IBS-D)	N/A (Mangel and Chaturvedi, 2008)	2	Randomized, Double-Blind, Placebo-Controlled	241	125, 250, 500 mg BID vs. Placebo	Change in stool consistency	Not Met: No significant improvement in stool consistency. Post-hoc finding of improved pain-free days in women.
Microvillus Inclusion Disease (Pediatric)	NCT06721871	2	Open-Label, Dose-Escalation	(Recruiting)	Ascending doses of powder for oral solution	Safety and tolerability	Ongoing.
Traveler's Diarrhea	N/A	2/3	Randomized, Placebo-Controlled	N/A	125, 250, 500 mg	Time to last unformed stool (TLUS)	Met: Significant reduction in duration of diarrhea vs. placebo.
Acute Infectious Diarrhea (Cholera)	N/A (Bardhan et al.)	2	Randomized, Placebo-Controlled	98	250 mg QID vs. Placebo	Resolution of watery diarrhea within 48 hours	Met: 75% reduction in watery stool output vs. 37% for placebo.

Approved Indication: Non-Infectious Diarrhea in HIV/AIDS

The primary and only approved indication for Crofelemer is for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on stable antiretroviral therapy (ART).[1] Chronic diarrhea is a prevalent and burdensome complication in this population, with estimates suggesting it affects up to 60% of patients.[28] The etiology is multifactorial, often stemming from the direct effects of ART (particularly protease inhibitors) or from HIV-associated enteropathy, where the virus itself damages the gastrointestinal tract.[6] This persistent diarrhea can severely impair quality of life and, critically, may lead to poor adherence to life-saving ART regimens, increasing the risk of virologic failure and drug resistance.[10]

The approval of Crofelemer by the U.S. FDA on December 31, 2012, was a landmark event, as it provided the first specifically indicated and evidence-based treatment for this condition.[6] Approval was granted based on the robust data from the pivotal Phase 3 ADVENT (Antidiarrhea Therapy in HIV Disease-Emerging Treatment Concepts) trial.[7]

The ADVENT trial was a large, multicenter, randomized, double-blind, placebo-controlled study with a two-stage adaptive design, enrolling 376 HIV-positive patients.[6] Eligible participants were on stable ART and had a history of non-infectious diarrhea (defined as watery bowel movements on ≥5 of 7 days) for at least one month.[6] The first stage of the trial served as a dose-ranging study, evaluating three doses of Crofelemer (125 mg, 250 mg, and 500 mg, all administered twice daily) against a placebo.[7] Based on a prospective analysis of efficacy and safety from this stage, the 125 mg twice-daily dose was selected as the optimal dose to be carried into the second stage, which enrolled a new cohort of patients to confirm its efficacy against placebo.[7]

The primary efficacy endpoint for the combined analysis of both stages was the proportion of patients who achieved a "clinical response" during the 4-week placebo-controlled phase. This was stringently defined as having two or fewer watery stools per week for at least two of the four weeks of treatment.[7] The results demonstrated a clear and statistically significant benefit for Crofelemer. In the combined analysis, 17.6% of patients receiving Crofelemer 125 mg twice daily achieved a clinical response, more than double the 8.0% response rate observed in the placebo group (one-sided p=0.01).[6] In addition to meeting the primary endpoint, the trial also showed that Crofelemer led to statistically significant improvements in secondary endpoints, including a greater reduction from baseline in the average number of daily watery bowel movements (p=0.04) and an improved daily stool consistency score (p=0.02) compared to placebo.[7]

The durability of the treatment effect was assessed in a 20-week, open-label extension phase where all patients received Crofelemer. The response rates continued to improve over this longer period, with the percentage of weekly responders reaching a plateau of 40% to 56% between weeks 11 and 24.[7] Further analysis showed that after 20 weeks of continuous treatment, approximately 9 out of 10 patients reported a decrease in the frequency of watery stools, and more than half of the patients reported having no watery stools at all.[38]

Investigational Uses and Future Potential

Beyond its established role in HIV-associated diarrhea, Crofelemer is being actively investigated for a range of other conditions, reflecting a strategic effort to leverage its unique antisecretory mechanism. This development program has yielded mixed results, providing valuable lessons that have guided a recent pivot towards rare diseases with high unmet medical needs.

Supportive Care in Oncology (Cancer Therapy-Related Diarrhea - CTD)

A strong mechanistic rationale supports the use of Crofelemer for CTD. Many modern targeted cancer therapies, particularly those inhibiting epidermal growth factor receptors (EGFR) or HER2, are known to induce a secretory diarrhea by activating the same CFTR and CaCC intestinal chloride channels that Crofelemer inhibits.[40] This provided the basis for the Phase 3 OnTARGET trial (NCT04538625), which evaluated Crofelemer 125 mg twice daily for the

prophylaxis of diarrhea in adult patients with various solid tumors receiving targeted therapies.[11]

The trial enrolled 287 patients with 10 different types of solid tumors who were being treated with 24 different targeted therapies, either alone or in combination with chemotherapy.[11] Despite the strong rationale, the trial

failed to meet its primary endpoint. Prophylaxis with Crofelemer did not result in a statistically significant reduction in the incidence of diarrhea compared to placebo across the entire study population.[11] The company attributed this outcome to the highly heterogeneous nature of the patient population and the variety of cancer therapies used.[11] This experience underscores the challenge of demonstrating efficacy for a supportive care agent in a broad, "all-comers" oncology setting. However, a preliminary subgroup analysis provided a signal of potential efficacy, showing a "clinically meaningful benefit" in patients with breast and respiratory cancers. These two groups constituted over 75% of the trial participants, and it is plausible that the specific targeted therapies used for these cancers induce a more uniformly secretory diarrhea, making them more amenable to treatment with Crofelemer. The company intends to conduct a full analysis of the data and discuss a potential path forward with the FDA for these more specific patient populations.[11]

Rare Gastrointestinal Diseases (Orphan Indications)

Following the challenges in broader indications, there has been a clear and strategic pivot towards developing Crofelemer for rare diseases where severe secretory diarrhea is a central feature of the pathophysiology. This strategy is bolstered by multiple Orphan Drug Designations (ODDs) from both the FDA and the EMA, which provide significant development incentives, including tax credits, fee waivers, and a period of market exclusivity upon approval.[12]

• Short Bowel Syndrome (SBS): SBS is a condition of malabsorption resulting from the surgical removal of a large portion of the small intestine. Patients often suffer from severe chronic diarrhea and fluid loss. Crofelemer has received ODD for SBS from the FDA (August 2017) and the EMA (December 2021).[1] The therapeutic hypothesis is that by reducing the secretory component of diarrhea, Crofelemer can decrease intestinal fluid output, reduce the need for parenteral nutrition, and potentially improve nutrient absorption.[44] Several clinical efforts are underway, including investigator-initiated trials and Phase 2 studies, to evaluate its efficacy in this population.[12]
• Microvillus Inclusion Disease (MVID): MVID is an extremely rare and life-threatening congenital diarrheal disorder that presents in newborns with intractable, high-volume secretory diarrhea, leading to severe dehydration and intestinal failure.[13] Crofelemer has received ODD for MVID from the EMA (October 2022) and the FDA (February 2023).[1] A Phase 2 clinical trial (NCT06721871) is actively recruiting pediatric patients to evaluate a new powder for oral solution formulation of Crofelemer, which is better suited for this patient population.[46]
• Cholera: Cholera is an acute infectious disease caused by the bacterium Vibrio cholerae, which produces a toxin that leads to massive, life-threatening secretory diarrhea. Early clinical data has shown that Crofelemer can significantly reduce watery stool output in patients with cholera.[5] In recognition of its potential, the FDA granted Crofelemer an ODD for the treatment of diarrhea in cholera in December 2024.[12]

Other Diarrheal Conditions

Crofelemer has also been evaluated in other common diarrheal conditions. Clinical studies in traveler's diarrhea and acute infectious diarrhea (caused by pathogens such as E. coli and Salmonella) have demonstrated that Crofelemer can reduce the duration of illness and the frequency of watery stools.[5] In

irritable bowel syndrome with diarrhea (IBS-D), a 12-week, placebo-controlled trial did not show a significant benefit on the primary endpoint of stool consistency.[2] However, an intriguing post-hoc analysis of this study revealed a statistically significant increase in the number of abdominal pain-free days among female participants, suggesting a potential visceral analgesic effect that may warrant further investigation.[21]

Comprehensive Safety and Tolerability Profile

Clinical Trial Safety Data

Across its extensive clinical development program, Crofelemer has consistently demonstrated a favorable safety and tolerability profile, a characteristic largely attributable to its minimal systemic absorption and localized action within the gut. In placebo-controlled trials, the overall incidence of adverse events (AEs) in patients receiving Crofelemer has been comparable to that observed in patients receiving placebo.[5]

The largest and most definitive safety dataset comes from the pivotal ADVENT trial in HIV-positive patients. In the 4-week placebo-controlled phase of this study, the most common adverse reactions (defined as occurring in ≥3% of patients and at a higher rate than placebo) were upper respiratory tract infection, bronchitis, cough, flatulence, and increased bilirubin.[5] Other commonly reported AEs (occurring in 1% to 10% of patients) included nausea, abdominal distension, back pain, arthralgia (joint pain), and urinary tract infection.[26] Notably, constipation, a frequent side effect of antimotility agents, was reported in less than 2% of patients on Mytesi, underscoring the mechanistic difference of the drug.[26] The incidence of these common AEs is detailed in the table below.

Adverse Reaction	Crofelemer 125 mg BID (N = 229) n (%)	Placebo (N = 274) n (%)
Upper respiratory tract infection	13 (5.7%)	10 (3.6%)
Bronchitis	9 (3.9%)	3 (1.1%)
Cough	8 (3.5%)	4 (1.5%)
Flatulence	7 (3.1%)	5 (1.8%)
Increased bilirubin	7 (3.1%)	3 (1.1%)

Data derived from prescribing information reflecting the ADVENT trial.[50]

Serious adverse events (SAEs) and discontinuations due to AEs were infrequent during the placebo-controlled phase of the ADVENT trial. Two patients (<1%) in the Crofelemer group experienced an SAE, compared to four patients (3%) in the placebo group. Importantly, no patient treated with Crofelemer discontinued the study due to an adverse event during this phase.[25]

With respect to hepatotoxicity, Crofelemer is considered to have a very low risk of causing liver injury. While long-term, open-label studies noted mild and self-limiting elevations in serum alanine aminotransferase (ALT) in 2.7% of treated subjects, these were generally not considered clinically significant and rarely led to dose modification.[26] Crucially, there have been no reported cases of clinically apparent acute liver injury attributable to Crofelemer. The National Institute of Diabetes and Digestive and Kidney Diseases' LiverTox database assigns Crofelemer a likelihood score of "E," signifying it is an "unlikely cause of clinically apparent liver injury," a conclusion based primarily on its negligible systemic absorption.[1]

In the target population of HIV-positive patients, it is vital that an adjunctive therapy does not interfere with the efficacy of ART. Clinical studies have confirmed that treatment with Crofelemer has no appreciable negative impact on key immunological and virological parameters, including HIV viral load and CD4+ cell counts.[9]

Drug Interactions and Contraindications

The potential for drug-drug interactions with Crofelemer is low, particularly concerning systemic interactions. Its minimal absorption prevents it from reaching clinically relevant concentrations in the plasma, thereby avoiding interactions mediated by hepatic cytochrome P450 (CYP) enzymes or other systemic pathways.[1] Clinical pharmacokinetic studies have confirmed this, showing no significant effect of Crofelemer on the systemic exposure of co-administered antiretroviral drugs.[53]

However, because the drug is present at high concentrations within the gastrointestinal lumen, there is a theoretical potential for local drug interactions at the level of the gut wall. In vitro studies have shown that Crofelemer can inhibit the activity of the CYP3A4 enzyme as well as the drug transporters MRP2 and OATP1A2 at concentrations that could be expected in the gut.[8] This could potentially alter the absorption of other orally administered drugs that are substrates of these systems. While clinical evidence of such interactions is lacking, it is advisable for clinicians to monitor for potential changes in the efficacy or toxicity of concomitant oral medications, particularly those with a narrow therapeutic index that are metabolized by CYP3A4.[35]

There are no specific contraindications listed for the use of Crofelemer.[52] The most significant warning and precaution associated with its use is the critical need to

rule out infectious etiologies of diarrhea before initiating treatment.[8] Crofelemer is not indicated for the treatment of infectious diarrhea. If an infectious cause is not considered and treatment is started presumptively, there is a risk that the patient will not receive appropriate antimicrobial therapy, potentially leading to a worsening of the underlying infection.[39] Therefore, a thorough clinical evaluation to exclude bacterial, viral, or parasitic causes is essential prior to prescribing Crofelemer.

Use in Specific Populations and Toxicology

The use of Crofelemer in specific populations has been evaluated, with recommendations based on available data.

• Pregnancy: Crofelemer is classified as Pregnancy Category C. Animal reproduction studies in rats at doses up to 177 times the recommended human dose revealed no evidence of fetal harm. However, in pregnant rabbits, doses approximately 96 times the human dose caused an increase in abortions and fetal resorptions, although these effects may have been related to maternal toxicity. As there are no adequate and well-controlled studies in pregnant women, Crofelemer should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.[50]
• Breastfeeding: It is not known whether Crofelemer is excreted in human milk. However, for its approved indication, the Centers for Disease Control and Prevention (CDC) recommend that HIV-1 infected mothers should not breastfeed their infants to avoid the risk of postnatal transmission of HIV-1, regardless of their medication regimen.[36]
• Pediatric Use: For its approved indication in HIV-associated diarrhea, the safety and effectiveness of Crofelemer have not been established in patients under 18 years of age.[50] However, the drug is actively being developed for pediatric use in the context of rare congenital diarrheal disorders. A new powder for oral solution formulation is currently being evaluated in clinical trials for infants and children with MVID.[46]
• Geriatric Use: Clinical trials of Crofelemer did not include a sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Therefore, no specific geriatric dosing recommendations are available.[52]

Nonclinical toxicology studies have established oral median lethal dose (LD50​) values of 300 mg/kg in mice and 980 mg/kg in rats.[55] The drug is not listed as a carcinogen by major toxicology programs such as ACGIH, IARC, NIOSH, NTP, or OSHA.[55]

Global Regulatory and Dosing Information

Regulatory History and Status

Crofelemer has a distinct regulatory history, marked by its landmark approval in the United States as a botanical drug and a growing number of orphan drug designations globally that are shaping its future development.

United States Food and Drug Administration (FDA):

The New Drug Application (NDA) for Crofelemer received Priority Review designation from the FDA in February 2012, signaling its potential to address a significant unmet medical need.16 On

December 31, 2012, the FDA approved Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.[5] This approval was notable as Crofelemer became the first orally administered botanical drug to be approved by the agency.[23] The product was initially launched under the brand name Fulyzaq® and was later rebranded as Mytesi® in October 2016.[16]

In addition to its marketing approval, the FDA has granted Crofelemer several Orphan Drug Designations (ODDs), which facilitate the development of drugs for rare diseases:

• Short Bowel Syndrome (SBS): Granted in August 2017.[18]
• Microvillus Inclusion Disease (MVID): Granted in February 2023.[18]
• Diarrhea in Cholera: Granted in December 2024.[12]

European Medicines Agency (EMA):

As of late 2024, Crofelemer is not approved for marketing in the European Union. However, its developer is actively pursuing a regulatory pathway in Europe focused on rare diseases. This strategy is supported by multiple ODDs from the EMA, which provide scientific and regulatory support during development and offer ten years of market exclusivity if the drug is eventually approved.12 The EMA has granted ODDs for:

• Short Bowel Syndrome (SBS): Granted in December 2021.[1]
• Microvillus Inclusion Disease (MVID): Granted in October 2022.[1]

Other Regions:

The global commercialization strategy for Crofelemer involves partnerships and distribution agreements in various regions. An agreement with Glenmark Pharmaceuticals covers the exclusive distribution rights for Crofelemer in 140 emerging markets, including India.5 More recently, an exclusive distribution and license agreement was established with Quadri Pharmaceuticals to commercialize the drug in several Middle Eastern countries, including Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman.57

Date (Year-Month)	Regulatory Body / Region	Action / Milestone	Indication / Details
2012-12	U.S. FDA	Marketing Approval	Non-infectious diarrhea in adults with HIV/AIDS on ART
2017-08	U.S. FDA	Orphan Drug Designation	Short Bowel Syndrome (SBS)
2021-12	EMA	Orphan Drug Designation	Short Bowel Syndrome (SBS)
2022-10	EMA	Orphan Drug Designation	Microvillus Inclusion Disease (MVID)
2023-02	U.S. FDA	Orphan Drug Designation	Microvillus Inclusion Disease (MVID)
2024-12	U.S. FDA	Orphan Drug Designation	Diarrhea in Cholera

Dosing, Administration, and Formulations

The dosing and administration guidelines for Crofelemer are based on the regimen established as safe and effective in the pivotal ADVENT trial.

• Approved Dosage (Adults): The recommended dose for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS is one 125 mg tablet taken orally twice daily.[8] No dosage adjustments are recommended based on the patient's CD4+ T-cell count or HIV viral load.[8]
• Administration: The tablets are formulated with a delayed-release (enteric) coating to ensure delivery to the intestine. Therefore, patients should be instructed to swallow the tablets whole. They should not be crushed or chewed, as this would disrupt the coating.[8] Crofelemer can be administered without regard to meals, providing flexibility for the patient.[8]
• Dosage Forms and Strengths: Crofelemer is commercially available as 125 mg delayed-release tablets.[8]
• Investigational Formulations: To address the needs of pediatric populations and patients who may have difficulty swallowing tablets, a powder for oral solution formulation is under development. This formulation is currently being evaluated in clinical trials for rare congenital diarrheal disorders such as MVID and SBS.[46]

Concluding Analysis and Strategic Recommendations

Synthesis of Clinical Value and Market Position

Crofelemer occupies a unique and significant position in the therapeutic landscape. Its journey from a traditional Amazonian remedy to an FDA-approved pharmaceutical is a testament to the potential of ethnobotany when subjected to rigorous scientific and clinical validation. It stands as a landmark drug in several key respects. First, as the first orally administered botanical drug approved by the FDA, it has forged a regulatory path for complex, plant-derived products. Second, as a first-in-class antisecretory agent, it introduced a novel mechanism of action for the treatment of diarrhea. Instead of targeting gut motility, Crofelemer normalizes the underlying secretory pathophysiology, offering a more targeted approach for specific types of diarrhea.

Its primary clinical value lies in addressing a clear and persistent unmet medical need: chronic, non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. For this population, Crofelemer offers a proven, effective therapy that can improve quality of life and potentially enhance adherence to essential ART. The value proposition is powerfully supported by its exceptional safety profile, which is a direct and predictable consequence of its large polymeric structure and consequent lack of systemic absorption. This allows it to be used chronically in a patient population often subject to polypharmacy and concerns about systemic toxicities.

The clinical development program has also provided critical strategic lessons. The success in the relatively homogeneous population of the ADVENT trial stands in contrast to the failure to meet the primary endpoint in the highly heterogeneous OnTARGET trial for cancer therapy-related diarrhea. This outcome highlights the importance of precise patient selection, suggesting that Crofelemer's efficacy is maximized in diarrheas with a well-defined and dominant secretory mechanism. In response, the strategic pivot towards rare congenital diarrheal disorders like short bowel syndrome and microvillus inclusion disease is both logical and promising. In these conditions, the pathophysiology is directly aligned with Crofelemer's antisecretory mechanism, and the high unmet need, coupled with the benefits of orphan drug designation, creates a viable and impactful path for future development.

Future Directions and Unmet Needs

Based on the comprehensive analysis of the available data, several strategic recommendations and areas of unmet need can be identified for the future development and clinical application of Crofelemer.

Recommendation 1 (Clinical Research Strategy): Future clinical trials in oncology should move away from a broad, "all-comers" approach to CTD. Instead, research should focus on well-defined, homogeneous patient populations where a secretory mechanism is known to be the primary driver of diarrhea. This would include, for example, trials specifically in patients with HER2-positive breast cancer receiving tyrosine kinase inhibitors or in patients with colorectal cancer receiving EGFR inhibitors. Furthermore, designing head-to-head comparative effectiveness trials against the current standard of care, such as loperamide, in these specific populations would be invaluable for defining Crofelemer's precise role in the oncology supportive care armamentarium.

Recommendation 2 (Pharmacological Clarification): The theoretical risk of local, gut-level drug-drug interactions via inhibition of CYP3A4 and intestinal transporters requires definitive clinical investigation. An in vivo drug interaction study using a sensitive oral CYP3A4 substrate (e.g., midazolam), as previously recommended by the FDA, is a critical next step. The results of such a study would provide clear, evidence-based guidance for clinicians and would be essential for ensuring the safe use of Crofelemer in patients on complex medication regimens, particularly in the HIV and oncology settings.

Recommendation 3 (Formulation and Pediatric Development): The ongoing development of a powder for oral solution formulation is a crucial initiative that should be prioritized. This formulation is essential for realizing the full therapeutic potential of Crofelemer in rare pediatric diseases like MVID and SBS, where a tablet formulation is impractical. Continued investment in pediatric clinical trials and formulation development will be key to addressing the profound unmet needs in these vulnerable populations.

Unmet Need (Predictive Biomarkers): A significant unmet need remains in optimizing patient selection for Crofelemer therapy. While the ADVENT trial demonstrated statistically significant efficacy, the absolute clinical response rate of 17.6% indicates that a substantial proportion of patients with non-infectious diarrhea in the HIV population do not achieve the primary endpoint. Future research should focus on identifying clinical characteristics or biomarkers that can predict which patients are most likely to respond to Crofelemer. This could involve analyzing stool for markers of secretory activity or exploring genetic markers related to ion channel expression, ultimately enabling a more personalized and effective application of this novel therapy.

Works cited

1. Crofelemer - PubChem, accessed September 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Crofelemer
2. Clinical Policy: Crofelemer (Mytesi) - Health Net, accessed September 22, 2025, https://healthnet.com/static/general/unprotected/html/national/pa_guidelines/842.pdf
3. The development of Crofelemer: Connecting ethnobotany, conservation, biocultural diversity, global public health and indigenous knowledge - Thieme E-Books & E-Journals -, accessed September 22, 2025, https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0032-1320220
4. Crofelemer, an Antisecretory Antidiarrheal Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal Chloride Channels, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2802429/
5. Crofelemer - Wikipedia, accessed September 22, 2025, https://en.wikipedia.org/wiki/Crofelemer
6. Crofelemer Is Approved for Noninfectious Diarrhea in HIV-Infected Patients, accessed September 22, 2025, https://www.jwatch.org/ac201301070000001/2013/01/07/crofelemer-approved-noninfectious-diarrhea-hiv
7. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/24334179/
8. Crofelemer Monograph for Professionals - Drugs.com, accessed September 22, 2025, https://www.drugs.com/monograph/crofelemer.html
9. Crofelemer: A Review of Its Use in the Management of Non-Infectious Diarrhoea in Adult Patients With HIV/AIDS on Antiretroviral Therapy - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/23807722/
10. Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Doubl, accessed September 22, 2025, https://www.tandfonline.com/doi/pdf/10.1310/hct1406-261
11. Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy | OncLive, accessed September 22, 2025, https://www.onclive.com/view/crofelemer-misses-diarrhea-end-point-in-patients-with-solid-tumors-receiving-targeted-therapy
12. FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera - FirstWord Pharma, accessed September 22, 2025, https://firstwordpharma.com/story/5922062
13. European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication | Jaguar Health, Inc., accessed September 22, 2025, https://jaguarhealth.gcs-web.com/news-releases/news-release-details/european-medicines-agency-grants-orphan-drug-designation-0
14. FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera, accessed September 22, 2025, https://jaguarhealth.gcs-web.com/news-releases/news-release-details/fda-approves-orphan-drug-designation-jaguar-healths-crofelemer
15. Crofelemer delayed-release tablets - Cleveland Clinic, accessed September 22, 2025, https://my.clevelandclinic.org/health/drugs/18993-crofelemer-delayed-release-tablets
16. Mytesi (crofelemer) FDA Approval History - Drugs.com, accessed September 22, 2025, https://www.drugs.com/history/mytesi.html
17. SP 303 | 148465-45-6 - ChemicalBook, accessed September 22, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB71313500.htm
18. Crofelemer - Orphanet, accessed September 22, 2025, https://www.orpha.net/en/drug/substance/622290?name=
19. Definition of crofelemer - NCI Drug Dictionary, accessed September 22, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/crofelemer
20. 202292Orig1s000 - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000EA.pdf
21. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/publication/8473687_A_novel_extract_SB-300_from_the_stem_bark_latex_of_Croton_lechleri_inhibits_CFTR-mediated_chloride_secretion_in_human_colonic_epithelial_cells
22. Crofelemer Oral Delayed Release Tablet - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202292.pdf
23. Profile of crofelemer for the symptomatic treatment of diarrhea in HIV-infected persons, accessed September 22, 2025, https://www.dovepress.com/profile-of-crofelemer-for-the-symptomatic-treatment-of-diarrhea-in-hiv-peer-reviewed-fulltext-article-BTAT
24. Dragon's Blood Uses, Benefits & Dosage - Drugs.com, accessed September 22, 2025, https://www.drugs.com/npp/dragon-s-blood.html
25. ADVENT Trial: Crofelemer for the Treatment of Secretory Diarrhea in HIV+ Individuals - NATAP, accessed September 22, 2025, https://natap.org/2013/HIV/CROI889.pdf
26. Crofelemer - LiverTox - NCBI Bookshelf, accessed September 22, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548325/
27. Crofelemer | CAS 148465-45-6 - AbMole BioScience, accessed September 22, 2025, https://www.abmole.com/products/crofelemer.html
28. 202292Orig1s000 - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000SumR.pdf
29. FDA approves first anti-diarrheal drug for HIV/AIDS patients - NATAP, accessed September 22, 2025, https://www.natap.org/2013/HIV/010713_02.htm
30. 202292Orig1s000 - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000Risk.pdf
31. (PDF) Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea - ResearchGate, accessed September 22, 2025, https://www.researchgate.net/publication/236329333_Crofelemer_a_novel_antisecretory_agent_approved_for_the_treatment_of_HIV-associated_diarrhea
32. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/19808995/
33. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS - PMC, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3722035/
34. Management of Noninfectious Diarrhea Associated With HIV and Highly Active Antiretroviral Therapy, accessed September 22, 2025, https://www.ajmc.com/view/a472_sep13_macarthur_s238
35. Mytesi (crofelemer) dosing, indications, interactions, adverse effects, and more, accessed September 22, 2025, https://reference.medscape.com/drug/mytesi-crofelemer-999806
36. Crofelemer: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 22, 2025, https://www.rxlist.com/crofelemer/generic-drug.htm
37. 202292Orig1s000 - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000ClinPharmR.pdf
38. Results with Mytesi - Mytesi® (crofelemer) Symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS, accessed September 22, 2025, https://mytesi.com/results-with-mytesi/
39. Mytesi® (crofelemer) Symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS, accessed September 22, 2025, https://mytesi.com/
40. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10807780/
41. Abstract PO3-13-01: ONTARGET: Phase 3 randomized, double-blind, placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors receiving targeted therapies with or without standard chemotherapy | Cancer Research - AACR Journals, accessed September 22, 2025, https://aacrjournals.org/cancerres/article/84/9_Supplement/PO3-13-01/744100/Abstract-PO3-13-01-ONTARGET-Phase-3-randomized
42. Crofelemer Completed Phase 3 Trials for Symptomatic Relief of Diarrhea / Adult Solid Tumor / Chemotherapy-related Diarrhea / Prophylaxis of Diarrhea / Cancer Therapy-Related Diarrhea / Targeted Therapy-related Diarrhea Prevention - DrugBank, accessed September 22, 2025, https://go.drugbank.com/drugs/DB04941/clinical_trials?conditions=DBCOND0029974%2CDBCOND0132011%2CDBCOND0130252%2CDBCOND0132012%2CDBCOND0132013%2CDBCOND0132014&phase=3&purpose=prevention&status=completed
43. European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health's Italian Subsidiary, for Short Bowel Syndrome - ACCESS Newswire, accessed September 22, 2025, https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/european-medicines-agency-grants-orphan-drug-designation-for-crofeleme-677154
44. EU/3/21/2541 - orphan designation for treatment of short bowel syndrome | European Medicines Agency (EMA), accessed September 22, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2541
45. Crofelemer: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 22, 2025, https://go.drugbank.com/drugs/DB04941
46. U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins - BioSpace, accessed September 22, 2025, https://www.biospace.com/press-releases/u-s-investigator-initiated-trial-iit-to-evaluate-jaguar-healths-crofelemer-for-short-bowel-syndrome-with-intestinal-failure-sbs-if-begins
47. Rare Diseases Recruiting Phase 2 Trials for Crofelemer (DB04941) | DrugBank Online, accessed September 22, 2025, https://go.drugbank.com/indications/DBCOND0004874/clinical_trials/DB04941?phase=2&status=recruiting
48. Crofelemer, a novel agent for treatment of secretory diarrhea - PubMed, accessed September 22, 2025, https://pubmed.ncbi.nlm.nih.gov/20388859/
49. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome - PMC - PubMed Central, accessed September 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6970555/
50. FULYZAQ (crofelemer) label - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf
51. Crofelemer Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 22, 2025, https://www.drugs.com/sfx/crofelemer-side-effects.html
52. MYTESI® (crofelemer) delayed‐release tablets, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202292s007lbl.pdf
53. 202292Orig1s000 - accessdata.fda.gov, accessed September 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000MedR.pdf
54. Crofelemer (oral route) - Side effects & dosage - Mayo Clinic, accessed September 22, 2025, https://www.mayoclinic.org/drugs-supplements/crofelemer-oral-route/description/drg-20060700
55. CROFELEMER-Material Safety Datasheet - Amazon S3, accessed September 22, 2025, https://s3-us-west-2.amazonaws.com/drugbank/msds/DB04941.pdf?1370494440
56. Glenmark Pharmaceuticals Wins Right to Sell HIV Diarrhea Drug in 140 Countries, accessed September 22, 2025, https://www.biospace.com/glenmark-pharmaceuticals-wins-right-to-sell-hiv-diarrhea-drug-in-140-countries
57. UPDATED RELEASE: Jaguar Health Enters Exclusive Crofelemer Revenue Sharing Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets, accessed September 22, 2025, https://jaguarhealth.gcs-web.com/news-releases/news-release-details/updated-release-jaguar-health-enters-exclusive-crofelemer